Shares of Bioventus Inc. (NASDAQ:BVS – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the six ratings firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $16.60.
A number of brokerages recently issued reports on BVS. Cantor Fitzgerald reiterated an “overweight” rating and issued a $15.00 price target on shares of Bioventus in a report on Monday, August 17th. Barrington Research set a $18.00 price objective on Bioventus in a report on Thursday, August 6th. Wall Street Zen downgraded Bioventus from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 7th. Canaccord Genuity Group decreased their target price on Bioventus from $19.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, November 3rd. Finally, Weiss Ratings cut Bioventus from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, November 4th.
Read Our Latest Stock Analysis on Bioventus
Bioventus Price Performance
Shares of Bioventus stock opened at $10.46 on Tuesday. The stock has a market cap of $881.37 million, a price-to-earnings ratio of 13.08, a price-to-earnings-growth ratio of 1.39 and a beta of 0.66. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.16 and a current ratio of 1.68. The stock has a 50 day moving average price of $13.06 and a 200-day moving average price of $11.05. Bioventus has a one year low of $6.47 and a one year high of $15.89.
Bioventus (NASDAQ:BVS – Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The company reported $0.17 EPS for the quarter, meeting the consensus estimate of $0.17. Bioventus had a net margin of 9.78% and a return on equity of 26.31%. The company had revenue of $142.44 million for the quarter. Equities analysts expect that Bioventus will post 0.78 EPS for the current year.
Hedge Funds Weigh In On Bioventus
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Signaturefd LLC grew its holdings in shares of Bioventus by 2,809.1% during the third quarter. Signaturefd LLC now owns 1,920 shares of the company’s stock valued at $26,000 after buying an additional 1,854 shares during the last quarter. USA Financial Formulas purchased a new position in Bioventus in the 3rd quarter worth $42,000. Covestor Ltd raised its stake in Bioventus by 25.6% in the 3rd quarter. Covestor Ltd now owns 5,808 shares of the company’s stock worth $79,000 after acquiring an additional 1,182 shares during the last quarter. Quantum Financial Partners LLC lifted its position in Bioventus by 11.8% during the 3rd quarter. Quantum Financial Partners LLC now owns 14,200 shares of the company’s stock worth $194,000 after acquiring an additional 1,500 shares during the period. Finally, Pathstone Holdings LLC acquired a new stake in Bioventus during the 3rd quarter worth about $199,000. Hedge funds and other institutional investors own 62.94% of the company’s stock.
Bioventus Company Profile
Bioventus Inc. is a medical technology company focused on helping patients recover from musculoskeletal conditions and injuries. Its products and services support bone healing, pain management and surgical care. The company’s offerings include noninvasive devices that use ultrasound to support bone healing, injectable treatments for osteoarthritis pain, and surgical products such as bone graft materials and ultrasonic instruments used in procedures. Bioventus began operations in 2012, originating from businesses previously owned by Smith & Nephew.
Further Reading
- Five stocks we like better than Bioventus
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.
